Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Indolent Non-Hodgkin Lymphoma: early-phase trial registry
4 of 9 indexed Indolent Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Indolent Non-Hodgkin Lymphoma: 9 US clinical trials tracked, 4 recruiting.
Indolent Non-Hodgkin Lymphoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition indolent-non-hodgkin-lymphoma
OPEN 4 | RECR 44% | LATE 0 | EARLY 8 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Indolent Non-Hodgkin Lymphoma lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Indolent Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Indolent Non-Hodgkin Lymphoma is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Indolent Non-Hodgkin Lymphoma research.
Mayo Clinic accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Indolent Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Indolent Non-Hodgkin Lymphoma research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT06223542
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Mayo Clinic
NCT05876923
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
NCT04883437
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
NCT04223765
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Reid Merryman, MD
NCT05783596
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT04464200
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03884998
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
NCT03035331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Indolent Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Indolent Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Indolent Non-Hodgkin Lymphoma page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Indolent Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Indolent Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Indolent Non-Hodgkin Lymphoma condition card totals 9 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.